Immunophenotypic changes following menin inhibition in acute myeloid leukemia - PubMed
14 hours ago
- #AML
- #immunophenotype
- #menin inhibition
- Menin inhibition with revumenib shows antileukemic effects in AML by promoting hematopoietic differentiation.
- Clinical remissions observed in relapsed/refractory AML with KMT2A rearrangement or NPM1 mutation, leading to drug approval.
- Immunophenotypic changes post-treatment noted in 52% of patients, shifting from myeloid/stem-like to monocytic/myelomonocytic phenotypes or altering antigen expression.
- Morphologic remission with undetectable MRD linked to improved overall survival (23.6 months vs. 20.8 months with MRD, 3.2 months in non-responders).
- Flow cytometry essential for monitoring AML post-menin inhibition due to associated phenotypic changes.